Development milestone payment to Orexo after completed clinical study

Orexo AB has met the requirements for its first $6.5 million development milestone payment from Endo Pharmaceuticals Inc., following the completion of a clinical trial of Rapinyl™ (OX 20) with positive outcome. In this trial, the dose range to be used in the next stage of development was established. Orexo’s patented product Rapinyl™ (OX 20) is being studied for the management of breakthrough cancer pain . The two companies entered into a licensing agreement August 2004, which gives Endo Pharmaceuticals exclusive rights to develop and market Rapinyl™ (OX 20) for the North American market.

“With the completion of this study, we now look forward to Endo, a market leader in pain management, conducting a Phase III trial programme supporting approval in the US for breakthrough pain in opioid tolerant cancer patients. This programme is planned to start later this year”, said Zsolt Lavotha, president and CEO of Orexo AB. “This accomplishment demonstrates the strength of our business.” Rapinyl™ (OX 20) is an oral fast-dissolving sublingual tablet for the treatment of breakthrough cancer pain. It is based on Orexo’s unique proprietary technology for sublingual administration where a fast-dissolving tablet is placed under the tongue and the active substance is absorbed over the sublingual mucosa. It is believed this novel pharmaceutical preparation could provide fast onset of action, predictable, consistent drug delivery and added convenience for patients suffering from breakthrough pain. In return for the developing and marketing rights on the North American market, Orexo received an up-front payment of $10 million. In addition to the above indicated milestone payment, Orexo may receive up to $54.8 million, comprised of $15.6 million in license fees and $39.2 million in sales milestone payments. The agreement also provides for double-digit royalties upon commercial sales. The Japanese marketing rights for Rapinyl™ (OX 20) were licensed to Kyowa Hakko Kogyo Co. Ltd in January 2003. For further information, please contact: Zsolt Lavotha, President and CEO, Orexo AB +46 (0)18 780 88 00, e-mail: zsolt.lavotha@orexo.se Claes Wenthzel, CFO, Orexo AB +46 (0)18 780 88 00, e-mail: claes.wenthzel@orexo.se

About Us

Orexo develops improved pharmaceuticals based on innovative drug delivery technologies.The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The main market today is the US market for the treatment of opioid dependence where the product Zubsolv® is commercialized by Orexo. Other products are commercialized by license partners, including Zubsolv in markets outside of the US. Total net sales for 2016 amounted to SEK 705.9 million and the number of employees was 102. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) index and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where also research and development is performed, is located in Uppsala, Sweden.

Subscribe

Documents & Links